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vasodilationAbstract Antiphospholipid-mediated endothelium perturbation plays a role in
antiphospholipid syndrome (APS)-associated vasculopathy. Antiphospholipid anti-
bodies activate endothelium both in vitro and in vivo experimental models by
inducing a pro-inflammatory/-coagulant phenotype; the antibodies recognize h2
glycoprotein I (h2GPI) on human endothelial cells (EC) from different parts of the
vasculature.
In spite of such large in vitro evidence, few studies have addressed the issue
whether or not a comparable endothelial perturbation might be detectable in vivo.
We investigated several indirect ex vivo parameters of endothelial dysfunction:
plasma levels of soluble adhesion molecules (sADM), soluble thrombomodulin (sTM),
von Willebrand factor (vWF) and tissue plasminogen activator (t-PA) by solid-phase
assays. The study included: patients with primary antiphospholipid syndrome (n=32),
with the syndrome secondary to non-active systemic lupus erythematosus (SLE,
n=10), six patients with persistent antiphospholipid positivity at medium/high titre
without any clinical manifestation of the syndrome. Fifty-two age and sex matched
healthy subjects have been enrolled as controls. In addition, circulating endothelial
cells identified by flow cytometry and the brachial artery flow-mediated vaso-
dilation (FMV) were evaluated in 26 patients (20 primary and 6 lupus syndromes) and
30 healthy controls.Thrombosis Research (2004) 114, 329—3344 Elsevier Ltd. All rights reserved.
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significant increase in von Willebrand factor titres ( Pb0.05) was found. No
significant difference was found regarding the number of circulating endothelial
cells and flow-mediated vasodilation.
As a whole, these findings do suggest that antiphospholipid antibodies per se are
not able to support a full-blown endothelial perturbation in vivo. As shown in
antiphospholipid syndrome experimental animal models, a two-hit hypothesis is
suggested.
D 2004 Elsevier Ltd. All rights reserved.The ability of anti-phospholipid antibody (aPL) to
interact with endothelial cells (EC) was initially
suggested by Carreras and Vermylen [1]. They
demonstrated that lupus anticoagulant (LA) pos-
itive plasmas can suppress prostacyclin (PGI2)
release by vascular endothelium and in turn
affect the balance between endothelial PGI2 and
platelet thromboxane (TXA2) favouring an anti-
phospholipid syndrome (APS) hypercoagulable
state.
More recently, aPL IgG fractions were shown to
up-regulate endothelial expression of adhesion
molecules (ADM) and leukocyte adherence in vitro
[2]. At the same time, our group demonstrated that
such an activity was related to the anti-h2 glyco-
protein I (h2GPI) antibody specificity [3,4]. These
findings confirmed and extended the observation
that anti-cardiolipin IgG fractions activated EC in
the presence of h2GPI [2]. Following these studies,
other groups have confirmed this finding by using
both polyclonal and monoclonal aPL [5—8]. Inter-
estingly, aPL-mediated activation with ADM up-
regulation and pro-inflammatory cytokine secretion
was also found with human brain and skin primary
EC cultures, suggesting that such an effect might be
generalized to EC from different anatomical sites
[9].
It is important to point out that EC activation has
been reproduced in an in vivo experimental animal
APS model by Pierangeli at al. [7]. We recently
described an additional experimental in vivo
model, in which the infusion of IgG fractions with
strong anti-h2GPI activity but not control IgG can
induce leukoaggregation in the mesenteric rat
microcirculation when small amounts of lipopoly-
saccharide (LPS) are also injected at the same time
(Fischetti et al., 2004, personal communication).Table 1 Pleiotropic effect of aPL on endothelial cells
! Induction of a pro-inflammatory phenotype
! Tissue factor up-regulation
! Interaction with the protein C/S system
! Interaction with annexin V
! Interaction with the eicosanoid metabolism
! Induction of pre-proET-1 synthesis
! Induction of apoptosis
! Interaction with the late endosomesThe pleiotropic aPL effect on endothelial
cells
Several in vitro studies have shown that incubation
of EC with aPL can generate different effects on
endothelial function.In fact, besides the interference with the
eicosanoid metabolism and the induction of a pro-
adhesive phenotype, in vitro EC incubation with
aPL was reported to be able: (i) to up-regulate pro-
inflammatory and chemokine synthesis and secre-
tion [5—8], (ii) to modulate tissue factor (TF)
expression on the cell membrane [10,11], (iii) to
interfere with the protein C/S activation (review in
Ref. [12]), (iv) to displace annexin V binding to the
cell membrane [13], (v) to induce pre-pro-endo-
thelin (ET)-I synthesis [14], (vi) to favour an
apoptotic process [15,16] and (vii) to interact with
late endosomes [17] (Table 1).
As a whole, these effects might cooperate in
sustaining the endothelial perturbation that has
been suggested to play a pivotal pathogenic role in
APS-associated thrombophilic state.B2GPI as the main endothelial target antigen
for aPL
The demonstration that APS sera might recognize
antigenic determinants on EC membrane is the
necessary requisite to explain any interaction
between aPL and EC. By using an immunoprecipi-
tation assay that specifically radiolabelled HUVEC
apical cell surface proteins, two groups independ-
ently reported that APS sera immunoprecipitated
several EC membrane proteins with a molecular
weight ranging from 200 to 24 kDa [18,19]. Addi-
tional studies demonstrated that most of the
endothelial binding of aPL positive IgG fractions
was closely related to the anti-B2GPI activity
(review in Ref. [12]). Moreover, affinity purified
Inflammatory response and the endothelium 331polyclonal IgG or human monoclonal IgM with anti-
B2GPI specificity were found to recognize the
molecule on the EC surface membrane (review in
Ref. [12]).
Plasma proteins can adhere to EC and the
presence of B2GPI on the endothelium was sug-
gested to be, at least in part, due to such a general
phenomenon [20]. Actually, extensive washing and
culture in serum-free medium abolished the anti-
B2GPI reactivity with human umbilical cord vein
endothelial cell (HUVEC) monolayers that was in
turn restored by the addition of purified B2GPI
(review in Ref. [12]). Interestingly, such a phenom-
enon was found with HUVEC monolayers but not
with primary human EC cultures from skin or brain
micro-circulation [9]. It has been suggested that EC
might synthesize B2GPI themselves, but this has not
been substantiated (review in Ref. [12]).
Our own group demonstrated that B2GPI binds to
EC membranes through the putative PL-binding
site—a highly positively charged amino acid
sequence, located in the fifth domain of B2GPI
and previously shown to be involved in the binding
to cardiolipin-coated plates (review in Ref. [12]). It
has been suggested that heparan sulphate (HS)—the
major proteoglycan of the vascular endothelium
that constitutes the majority of the constitutive
endothelial anionic sites (review in Ref. [12])—
might be the corresponding negatively charged
structure for the B2GPI PL-binding site. In agree-
ment with such a hypothesis, HUVEC treatment
with heparitinase I, an enzyme able to cleave
specifically the A-N-acetyl-d-glycosaminidic link-
age in HS, significantly down-regulates h2GPI bind-
ing [9]. However, even the highest enzyme
concentrations gave an inhibition only up to 65%.
Although these findings indicate that HS is involved
in h2GPI binding, endothelial structures other than
HS should be considered to bind h2GPI.
Megalin—an endocytic receptor expressed on
placenta, kidney and other tissues—was reported
as a possible receptor for h2GPI [21]. However, Cao
et al. [22] showed that megalin-mRNA was not
expressed in both human vein and arterial umbilical
EC. Moreover, h2GPI binding to megalin was
reported to be Ca2+ ion-dependent; however, it is
not affected at all when HUVEC are cultured in
EDTA buffer (Meroni et al., personal communica-
tion). Altogether, these data are consistent with
the fact that megalin is not likely involved in EC
h2GPI binding.
More recently, h2GPI-binding proteins of ~70 and
~36 kDa from HUVEC and EAhy.926 cells were found
to be identical in amino acid sequence to annexin II
[23], an endothelial receptor for tissue plasmino-
gen activator (t-PA) [24—26]. In addition, radio-labelled h2GPI was found to adhere at high affinity
to Annexin II-transfected HEK 293 cells and the
adhesion to HUVEC was inhibited by anti-annexin II
antibodies [23]. The authors suggested that
Annexin II might represent an EC membrane
receptor for h2GPI.
Whatever the endothelial receptor for h2GPI is,
all the reported findings do support the hypothesis
that adhered h2GPI offers suitable epitopes for
anti-h2GPI antibodies either by making available
high density immunogenic epitopes or by displaying
new cryptic epitopes comparable to those detect-
able on ELISA plates either coated with anionic
phospholipids or g-irradiated.Endothelial activation by aPL
We and others have demonstrated that anti-h2GPI/
aPL antibodies were able to induce a pro-inflam-
matory and a pro-adhesive endothelial phenotype
through NF-kB activation in a similar way to that
found with standard agonists such as IL-1h, TNF-a
and LPS (review in Refs. [12,10]).
The NF-kB upstream EC activation pathways
have been recently investigated and reported to
be mediated by TRAF adapter family. TRAF-2 plays
a critical role in the presence of TNF-a; TRAF-6 is
employed in IL-1 and LPS signalling pathways [27]
and the MyD88 is identified as a further mediator
molecule involved in the IL-1/LPS activation cas-
cade. By using EC transfected with negative
dominants of TRAF-2/-6 or MyD88 our group
indicated that both human monoclonal IgM as well
as polyclonal IgG with anti-h2GPI activity induced a
signalling cascade comparable to that activated by
LPS or IL-1 [28]. Additional studies on the phos-
phorylation time kinetic of the IRAK—the first
kinase to be recruited by the IL-1/Toll-like receptor
(TLR) superfamily—suggested that the autoanti-
bodies activated EC through the TLR-4 involved in
LPS pathway [28].
TLR are key components of the innate immune
response able to recognize specific microbial
products, including LPS, bacterial lipoproteins,
peptidoglycan and bacterial DNA [29]. TLR expres-
sion is a widespread phenomenon in both lymphoid
and non-lymphoid tissues; in particular, TLR-4 is
found on EC, monocytes, neutrophils and dendritic
cells [29].
The relationship between TLRs and h2GPI is
apparently supported by the molecular mimicry
shared by h2GPI and different microbial patho-
gens—the natural ligands of TLRs [29,30,31,32,33].
We speculate that h2GPI might adhere to EC through
its PL-binding site and membrane anionic structures
P.L. Meroni et al.332and to interact with TLRs because of such a
homology. In turn, anti-h2GPI antibodies might
cross-link the complex eventually triggering the
inflammatory response through the TLR cascade.
As stated before, h2GPI can also bind annexin II.
However, it has been reported that annexin II does
not span the cell membrane, so the interaction
between h2GPI linked to annexin II and anti-h2GPI
antibodies would not be sufficient to induce any
intra-cytoplasmic signal and probably does require
a yet unknown badaptorQ protein [23—26]. We
speculate that h2GPI behaves as a bbridgeQ
between annexin II and TLR-4 on EC and at the
same time it might offer suitable antigenic epito-
pes for the circulating autoantibodies. Antibody
reactivity with such a complex could eventually
cluster the right membrane molecules and trigger
the cell signalling (Fig. 1).Do aPL induce an endothelial perturbation in
vivo too?
There is evidence that h2GPI can be expressed also
on EC in vivo. Antisera specific for human h2GPI give
a clear staining on trophoblast vessels in term
placentas [34,35]. However, in spite of the in vitro
data with human primary skin EC cultures, we did
not find a comparable endothelial staining in skin
biopsies obtained from normal donors or patientsFigure 1 Possible mechanisms for h2GPI binding to
endothelial cell membrane and cell signalling. Beta2GPI
can bind to endothelial cell membrane via the electric
charge interactions between the cationic phospholipid
binding site and anionic structures or as a ligand for
specific receptors (annexin II). The molecule can also
interact with the adjacent TLR because of its homology
with the microbial ligands for TLRs. Cell signalling might
take place once circulating anti-h2GPI antibodies recog-
nize the adhered molecules and cluster the complexes.affected by inflammatory disorders (unpublished
observations).
The question whether an endothelial perturba-
tion comparable to that detectable in in vitro
studies might be also detectable in vivo in APS
patients has been addressed by few studies. Differ-
ent indirect parameters of EC perturbation ex-vivo
have been investigated with no definite conclu-
sions. While some studies reported increased
plasma levels of single soluble ADM or endothelial
derived microparticles in APS patients, others did
not confirm these findings [36—39]. Additional
confounding variables—such as a concomitant asso-
ciated immune-mediated systemic inflammatory
disorder—did weaken the comparison. These find-
ings are in contrast to those that demonstrate the
aPL thrombogenic effect is closely mediated by
ADM expression in a murine experimental model
[40]. On the other hand, clear histological signs of
endothelial activation have been reported only in
biopsies taken from patients affected by the APS-
related heart valvulopathy [41].
We investigated several indirect in vivo param-
eters of endothelial dysfunction in aPL positive
patients: sADM: (sEselectin, sICAM-1, sVCAM-1),
sTM, vWF and t-PA evaluated by solid-phase
assays. Plasma levels of soluble ADM, as well as
levels of sTM, vWF and t-PA have been reported
to be increased in different disorders character-
ized by the presence of an endothelial perturba-
tion [42,43]. These parameters have been
investigated in: 32 patients with primary APS,
10 with APS secondary to systemic lupus eryth-
ematosus (SLE) and 4 SLE patients. All the
included SLE patients displayed non-active dis-
ease (ECLAM scoreV2) in order to avoid any
potential variables related to the immune-medi-
ated inflammation sustained by the lupus disease
itself. Additional two patients with persistent
antiphospholipid positivity at medium/high titre
but without any clinical manifestations and 52
age- and sex-matched controls were studied.
In addition a series of patients (20 primary and 6
SLE APS) was investigated for: (i) the presence of
circulating EC identified by flow cytometry and (ii)
the brachial artery flow-mediated vasodilation
(FMV) at rest, during reactive hyperemia and after
glyceryl nitrate. High levels of circulating EC have
been reported in patients suffering from disorders
characterized by an endothelial damage sustained
by systemic immune-mediated inflammation such
as in patients suffering from anti-neutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis or by
ischaemic processes [44]. An impaired endothelial-
dependent FMV has been also reported in compa-
rable conditions [45].
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reach a statistical significance in APS patients in
comparison with controls; t-PA levels showed an
increase in patients that however did not reach the
statistical significance. On the contrary, signifi-
cantly increased vWF titres were found in APS
patients. No significant difference between
patients and controls was found regarding the
number of circulating EC as well as the brachial
artery FMV.
As a whole, these findings do support that aPL
per se are not able to induce significant endothelial
perturbation in vivo. This finding is in line with the
results reported in the experimental animal models
in which the infusion of aPL does not trigger clot
formation or a strong endothelial activation in
uninjured vessels unless a mechanical trauma or
an inflammatory trigger is applied (Fischetti et al.,
7, 2004, submitted). In this regard, a two-hit
hypothesis has been suggested: aPL (first hit)
increases the risk of thrombotic events by inducing
a threshold endothelial perturbation; however,
another thrombophilic condition (second hit) is
required in order to trigger the clot formation.
Moreover, the two hit hypothesis might also explain
why patients persistently positive for aPL do display
thrombotic events only occasionally.Aknowledgments
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